DEVELOPMENTAL CHANGES OF HYDROXYUREA PHARMACOKIN ETICS IN CHILDREN WITH SICKLE CELL ANEMIA

被引：0

作者：

Dong, M. ^{[1
]}

Mizuno, T. ^{[1
]}

Good, A. ^{[2
]}

Hosawi, A. ^{[1
]}

Vinks, A. ^{[1
,3
]}

Ware, R. ^{[1
]}

McGann, P. ^{[4
]}

机构：

[1] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA

[2] Summit Country Day Sch, Cincinnati, OH USA

[3] Univ Cincinnati, Cincinnati, OH USA

[4] Rhode Isl Hosp, Providence, RI USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2023年 / 113卷

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

PWIV-003

引用

页码：S90 / S90

页数：1

共 2 条

[1] Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia [J].

Dong, Min ;

McGann, Patrick T. ;

Mizuno, Tomoyuki ;

Ware, Russell E. ;

Vinks, Alexander A. .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 81 (04) :742-752

[2] Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia [J].

Ware, Russell E. ;

Despotovic, Jenny M. ;

Mortier, Nicole A. ;

Flanagan, Jonathan M. ;

He, Jin ;

Smeltzer, Matthew P. ;

Kimble, Amy C. ;

Aygun, Banu ;

Wu, Song ;

Howard, Thad ;

Sparreboom, Alex .

BLOOD, 2011, 118 (18) :4985-4991

← 1 →